“An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review” (2024) Acta Medica Academica, 53(1), pp. 46–58. doi:10.5644/ama2006-124.443.